Argenx Nears Phase III In Myasthenia Gravis
Executive Summary
The reporting of positive topline Phase II results for a modified antibody fragment, efgartigimod, in myasthenia gravis by the Netherlands-based antibody-engineering biotech, argenx, has added to a growing list of new therapeutic approaches for the disorder.
You may also be interested in...
Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
Ra hopes to launch a Phase III program for zilucoplan next year, with a goal of bringing an alternative therapy for MG patients into competition with Alexion’s Soliris.
Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day
Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."